Literature DB >> 2557345

Mutations of GS alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity.

M Freissmuth1, A G Gilman.   

Abstract

We have introduced two types of mutations into cDNAs that encode the alpha subunit of Gs, the guanine nucleotide-binding regulatory protein that stimulates adenylyl cyclase. The arginine residue (Arg187) that is the presumed site of ADP-ribosylation of Gs alpha by cholera toxin has been changed to Ala, Glu, or Lys. The rate constant for hydrolysis of GTP by all of these mutants is reduced approximately 100-fold compared with the wild-type protein. As predicted from this change, these proteins activate adenylyl cyclase constitutively in the presence of GTP. Despite these substitutions, cholera toxin still catalyzes the incorporation of 0.2-0.3 mol of ADP-ribose/mol of mutant alpha subunit. The sequence near the carboxyl terminus of Gs alpha was altered to resemble those in Gi alpha polypeptides, which are substrates for pertussis toxin. Despite this change, the mutant protein is a poor substrate for pertussis toxin. Although this protein has unaltered rates of GDP dissociation and GTP hydrolysis, its ability to activate adenylyl cyclase in the presence of GTP is enhanced by 3-fold when compared with the wild-type protein but only when these assays are performed after reconstitution of Gs alpha into cyc- (Gs alpha-deficient) S49 cell membranes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557345

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Clinical spectrum and pathogenesis of pseudohypoparathyroidism.

Authors:  M A Levine
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Induced nucleotide specificity in a GTPase.

Authors:  Shu-ou Shan; Peter Walter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-27       Impact factor: 11.205

3.  Allosteric determinants in guanine nucleotide-binding proteins.

Authors:  Mark E Hatley; Steve W Lockless; Scott K Gibson; Alfred G Gilman; Rama Ranganathan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

4.  Gi3 does not contribute to the inhibition of adenylate cyclase when stimulation of an alpha 2-adrenergic receptor causes activation of both Gi2 and Gi3.

Authors:  S J McClue; E Selzer; M Freissmuth; G Milligan
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

5.  Phosphorylation of the spliced variant forms of the recombinant stimulatory guanine-nucleotide-binding regulatory protein (Gs alpha) by protein kinase C.

Authors:  N J Pyne; M Freissmuth; S Palmer
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

6.  Mono ADP-ribosylation inhibitors prevent inflammatory cytokine release in alveolar epithelial cells.

Authors:  Mariangela Del Vecchio; Enrico Balducci
Journal:  Mol Cell Biochem       Date:  2007-12-09       Impact factor: 3.396

7.  Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome.

Authors:  W F Schwindinger; C A Francomano; M A Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 8.  Mutations of signal-transducing G proteins in human disease.

Authors:  P Schnabel; M Böhm
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

9.  Stimulation of human umbilical vein endothelial cell proliferation by A2-adenosine and beta 2-adrenoceptors.

Authors:  V Sexl; G Mancusi; S Baumgartner-Parzer; W Schütz; M Freissmuth
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

10.  Genetic and physical interactions between Gα subunits and components of the Gβγ dimer of heterotrimeric G proteins in Neurospora crassa.

Authors:  Susan Won; Alexander V Michkov; Svetlana Krystofova; Amruta V Garud; Katherine A Borkovich
Journal:  Eukaryot Cell       Date:  2012-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.